APG Asset Management N.V. Decreases Stock Holdings in IQVIA Holdings Inc. $IQV

Key Points

• APG Asset Management N.V. reduced its stake in IQVIA Holdings Inc. by 4.5% in Q1, now holding 101,079 shares valued at approximately $16.5 million.
• The stock has seen significant activity from institutional investors, with Northwestern Mutual Wealth Management Co. increasing its position by 42.9% and AlphaQuest LLC by 101.8% in the same period.
• Analysts have varying ratings for IQVIA, with a consensus rating of "Moderate Buy" and a price target averaging $228.62, reflecting confidence in the company's performance and future earnings potential.

APG Asset Management N.V. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 101,079 shares of the medical research company's stock after selling 4,792 shares during the quarter. APG Asset Management N.V. owned 0.06% of IQVIA worth $16,497,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in IQV. Sowell Financial Services LLC purchased a new position in shares of IQVIA during the first quarter valued at approximately $305,000. Mather Group LLC. boosted its holdings in IQVIA by 83.5% in the first quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock worth $136,000 after acquiring an additional 350 shares in the last quarter. Private Advisor Group LLC raised its holdings in IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock worth $958,000 after buying an additional 566 shares during the last quarter. Park Avenue Securities LLC increased its holdings in shares of IQVIA by 40.4% in the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock worth $956,000 after purchasing an additional 1,562 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in IQVIA by 34.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock worth $2,338,000 after buying an additional 3,398 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Down 0.0%

Shares of IQVIA stock traded down $0.07 during trading on Thursday, reaching $188.73. The company's stock had a trading volume of 1,161,570 shares, compared to its average volume of 1,946,132. The company has a market cap of $32.08 billion, a price-to-earnings ratio of 27.31, a P/E/G ratio of 2.06 and a beta of 1.30. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a 50-day simple moving average of $176.32 and a two-hundred day simple moving average of $167.99.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the prior year, the firm earned $2.64 EPS. The firm's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IQV. Cowen restated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. cut their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Evercore ISI raised their target price on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Robert W. Baird upped their price objective on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Finally, Barclays upped their target price on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $228.62.

Insider Activity

In related news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.